DRI Ecstasy Plus Assay
Enzyme Immunoassay, Amphetamine. 510(k) K240670, from Microgenics Corporation (Fremont, CA). Product code DKZ, class 2.
As of Nov 20, 2026, K240670 is an FDA 510(k) held by Microgenics Corporation, substantially equivalent on Oct 30, 2024 after 233 days, with no recalls tied to it in FDA's recall database.
- Review time: 233 days
- Recalls: 0
The DRIâ„¢ Ecstasy Plus Assay is a homogeneous enzyme immunoassay intended for the qualitative or semiquantitative determination of ecstasy drugs in human urine. The assay provides a simple and rapid analytical screening procedure for detecting ecstasy drugs at a cutoff level of 500 ng/mL. The product is intended for use in clinical laboratories only.
- Dri Ecstasy Enzyme ImmunoassayK012110 · Microgenics Corp. · Aug 27, 2001
- AllTest Multi-Drug Rapid Test Cup; AllTest Multi-Drug Rapid Test Panel; AllTest Multi-Drug Rapid Test Cup Rx; AllTest…K233019 · Hangzhou AllTest Biotech Co., Ltd. · Dec 13, 2023
- Xenta Drug Screen Cup, Xenta Drug Screen DipcardK231137 · Xenta Biomedical Science Co., Ltd. · May 19, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Special
- Received
- Mar 11, 2024
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3100
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files